FACULTY
Michael J. Blaha, MD, MPH
Director of Clinical Research
Ciccarone Center for the Prevention of Cardiovascular Disease
Professor of Medicine
Johns Hopkins Medicine
Baltimore, MD
Charles Vega, MD, FAAFP
Health Sciences Clinical Professor
Department of Family Medicine
Assistant Dean for Culture and Community Education
University of California, Irvine School of Medicine
Irvine, CA
PROGRAM OVERVIEW
This innovative educational symposium is designed to advance interdisciplinary collaboration among clinicians who manage patients with cardio-renal-metabolic comorbidities. Using a combination of didactic lecture and simulation case challenges tailored to a primary audience of primary care physicians and a secondary audience of cardiologists, nephrologists, endocrinologists, hospitalists, physician assistants, nurse practitioners, pharmacists, and certified diabetes educators, this program aims to increase clinician knowledge of the application of SGLT2 inhibitors to the management of heart failure and chronic kidney disease as well as improve their ability to effectively communicate with all members of the multidisciplinary care team to optimize patient care.
TARGET AUDIENCE
This educational activity is intended for a primary audience of Primary Care Physicians, and a secondary audience of Cardiologists, Nephrologists, Endocrinologists, Hospitalists, Physician Assistants, Nurse Practitioners, Pharmacists, and Certified Diabetes Educators.
LEARNING OBJECTIVES
- Apply SGLT2 inhibitors to the management of heart failure and/or chronic kidney disease using relevant guidelines, clinical evidence, and FDA-approved indications
- Develop and utilize strategies for timely diagnosis and/or prompt treatment initiation in patients diagnosed with chronic kidney disease (CKD)
- Exhibit proficient collaboration and communication skills when working with endocrinologists, cardiologists, and nephrologists to employ a multidisciplinary care approach for patients with comorbidities involving the cardiovascular, renal, and metabolic systems
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NURSES (ANCC) CREDIT DESIGNATION
Amedco LLC designates this activity for a maximum of 1.25 ANCC contact hours.
AAFP ACCREDITATION
The AAFP has reviewed The Role of SGLT2 Inhibitors in the Treatment of Cardio-Renal-Metabolic Comorbidities: Implementing an Interdisciplinary Approach and deemed it acceptable for up to 1.25 Live AAFP Prescribed credits. Term of Approval is from 11/29/2023 to 11/29/2024. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 credit(s)TM toward the AMA Physician’s Recognition Award. When applying for the AMA PRA, Prescribed credit earned must be reported as Prescribed, not as Category 1.
COMMISION ON DIETETIC REGISTRATION
This program has received prior approval with the Commission on Dietetic Registration for dietitians and RDs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
Michael J. Blaha, MD, MPH discloses that he has received consulting fees from Novartis, Novo Nordisk, Bayer, Roche, Vectura, Agepha Pharma, Merck, and Boehringer Ingelheim. Dr. Blaha has served on the speakers’ bureau of Novo Nordisk. In addition, Dr. Blaha has conducted contracted research for Amgen, Novo Nordisk, and Bayer.
Charles Vega, MD, FAAFP discloses that he has received consulting fees from Boehringer Ingelheim.
All relevant financial relationships have been mitigated.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity:
- Matthew Frese, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
- Kia Jones, PhD, Medical Director of Med Learning Group, has nothing to disclose.
- Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
- Jessica Feygin, Associate Program Manager of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
- Daniel Dasilva, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (Physical, Dietary, etc.). Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: November 29, 2023
EXPIRATION DATE: November 29, 2024
Copyright © 2023 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
